Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Valneva SE (GB:0OB3)
LSE:0OB3
Holding GB:0OB3?
Track your performance easily
Earnings Data
Report Date
Mar 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.24Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 08, 2018
|% Change Since: -6.18%
|Next Earnings Date:Aug 02, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook for Valneva, with notable achievements in financial performance and R&D progress, particularly in Lyme disease and IXIARO sales. However, challenges remain, primarily due to the slow uptake of IXCHIQ in the US market and increased expenses related to R&D and marketing.Company Guidance
In the recent earnings call, Valneva provided guidance on several key financial metrics and strategic priorities. The company reported product sales of €112.5 million for the first nine months of 2024, reflecting a 12% growth over the prior year on a comparable basis. Despite a slow uptake of IXCHIQ in the US market, they narrowed their full-year product sales guidance to €160 million to €170 million. With a cash position of over €150 million, Valneva considers itself well-financed. The company anticipates generating cash from its commercial business again by 2025, driven by improved margins and top-line growth. R&D expenses are projected between €65 million and €75 million for the year, partly due to tech transfer costs to a new manufacturing site in Scotland. Valneva aims for sustained profitability from 2027, primarily driven by the Lyme disease vaccine program, with regulatory filings expected in 2026 and potential approvals in 2027. Additionally, the company highlighted significant potential in its R&D pipeline, including programs for chikungunya, Shigella, and Zika, and expressed confidence in achieving major catalysts, particularly with their Lyme disease vaccine, by the end of 2025.Product Sales and Cash Position
Product sales landed at more than €110 million for the first nine months of 2024. The company's cash position is over €150 million, indicating a strong financial position.
R&D Achievements
Strong R&D execution with Lyme disease vaccine development on track, Chik adolescents and pediatric data coming in as expected, and advancements in Shigella and Zika programs.
Financial Performance
Operating profit reported at €34.2 million compared to an operating loss of minus €57.2 million in the prior year. Adjusted EBITDA improved from minus €46 million to positive €48.6 million.
IXIARO Sales and Military Demand
IXIARO sales reached €66 million, increasing by 31% over the prior year, with strong demand from the US military.
---
GB:0OB3 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0OB3 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | €2.59 | €2.50 | -3.47% |
| Aug 13, 2024 | €3.11 | €3.35 | +7.72% |
| May 07, 2024 | €3.44 | €3.42 | -0.58% |
| Mar 20, 2024 | €3.71 | €3.44 | -7.28% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Valneva SE (GB:0OB3) report earnings?
Valneva SE (GB:0OB3) is schdueled to report earning on Mar 20, 2025, TBA Not Confirmed.
What is Valneva SE (GB:0OB3) earnings time?
Valneva SE (GB:0OB3) earnings time is at Mar 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Valneva SE stock?
The P/E ratio of Valneva is N/A.
What is GB:0OB3 EPS forecast?
GB:0OB3 EPS forecast for the fiscal quarter 2024 (Q4) is -0.09.
---